Characteristics for patients 18 to 54 years old
| Characteristics . | Haplo sibling, N = 218 . | Matched sibling, N = 843 . | P . |
|---|---|---|---|
| Recipient age, y | |||
| Median (range) | 41 (18-55) | 42 (18-55) | .36 |
| 18-39, n (%) | 102 (47) | 360 (43) | |
| 40-54, n (%) | 116 (53) | 483 (57) | |
| Recipient sex, n (%) | .07 | ||
| Male | 129 (59) | 441 (52) | |
| Female | 89 (41) | 402 (48) | |
| Donor age, y | .14 | ||
| Median (range) | 39 (15-69) | 40 (8-68) | |
| Disease, n (%) | .75 | ||
| AML | 146 (67) | 574 (68) | |
| ALL | 72 (33) | 269 (32) | |
| Disease status, n (%) | .07 | ||
| CR1 | 119 (55) | 533 (63) | |
| ≥CR2 | 48 (22) | 149 (18) | |
| Relapse/primary induction failure | 51 (23) | 161 (19) | |
| Disease risk index, n (%) | .98 | ||
| Low | 8 (3) | 32 (3) | |
| Intermediate | 135 (62) | 534 (63) | |
| High | 71 (33) | 261 (31) | |
| Not reported | 4 (2) | 16 (2) | |
| Graft type, n (%) | <.001 | ||
| Bone marrow | 125 (57) | 99 (12) | |
| Peripheral blood | 93 (43) | 744 (88) | |
| Conditioning intensity, n (%) | <.001 | ||
| Myeloablative | 131 (60) | 704 (84) | |
| Reduced intensity | 87 (40) | 139 (16) | |
| GVHD prophylaxis, n (%) | NA | ||
| CNI + MMF + PT-Cy | 218 (100) | — | |
| CNI + MMF | — | 167 (20) | |
| CNI + MTX | — | 542 (64) | |
| CNI alone | — | 134 (16) | |
| Transplant period, n (%) | <.001 | ||
| 2008-2011 | 52 (24) | 546 (65) | |
| 2012-2015 | 166 (76) | 297 (35) |
| Characteristics . | Haplo sibling, N = 218 . | Matched sibling, N = 843 . | P . |
|---|---|---|---|
| Recipient age, y | |||
| Median (range) | 41 (18-55) | 42 (18-55) | .36 |
| 18-39, n (%) | 102 (47) | 360 (43) | |
| 40-54, n (%) | 116 (53) | 483 (57) | |
| Recipient sex, n (%) | .07 | ||
| Male | 129 (59) | 441 (52) | |
| Female | 89 (41) | 402 (48) | |
| Donor age, y | .14 | ||
| Median (range) | 39 (15-69) | 40 (8-68) | |
| Disease, n (%) | .75 | ||
| AML | 146 (67) | 574 (68) | |
| ALL | 72 (33) | 269 (32) | |
| Disease status, n (%) | .07 | ||
| CR1 | 119 (55) | 533 (63) | |
| ≥CR2 | 48 (22) | 149 (18) | |
| Relapse/primary induction failure | 51 (23) | 161 (19) | |
| Disease risk index, n (%) | .98 | ||
| Low | 8 (3) | 32 (3) | |
| Intermediate | 135 (62) | 534 (63) | |
| High | 71 (33) | 261 (31) | |
| Not reported | 4 (2) | 16 (2) | |
| Graft type, n (%) | <.001 | ||
| Bone marrow | 125 (57) | 99 (12) | |
| Peripheral blood | 93 (43) | 744 (88) | |
| Conditioning intensity, n (%) | <.001 | ||
| Myeloablative | 131 (60) | 704 (84) | |
| Reduced intensity | 87 (40) | 139 (16) | |
| GVHD prophylaxis, n (%) | NA | ||
| CNI + MMF + PT-Cy | 218 (100) | — | |
| CNI + MMF | — | 167 (20) | |
| CNI + MTX | — | 542 (64) | |
| CNI alone | — | 134 (16) | |
| Transplant period, n (%) | <.001 | ||
| 2008-2011 | 52 (24) | 546 (65) | |
| 2012-2015 | 166 (76) | 297 (35) |
CNI, calcineurin inhibitor; CR, complete remission; Haplo, haploidentical; MMF, mycophenolate mofetil; MTX, methotrexate; NA, not applicable.